Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Chief Medical Officer | February 05, 2021 | February 08, 2021 |
| Sagimet Biosciences Inc.SGMT · Entity 5273 | Chief Medical Officer | May 28, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date February 05, 2021 · Filed February 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.41 · Expires 2031-02-04 | Direct | 200,000 |
Reported balance
After 2021-02-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-05 · Grant · Acquired 200,000 · Balance 200,000 F1: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 5, 2021, so that the total number of shares subject to this option becomes fully vested and exercisable on February 5, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 5, 2021, so that the total number of shares subject to this option becomes fully vested and exercisable on February 5, 2025.
Sagimet Biosciences Inc.
Report date May 28, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.27 · Expires 2036-05-27 | Direct | 35,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 35,000 · Balance 35,000 F1: The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following May 28, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following May 28, 2026, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2026 Filed Jun 2, 2026 01:15 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001104659-26-069123 · tm2616578-3_4seq1.xml · derivative · entry 1 Grauer Andreas · CIK 0001770511 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Series A Common Stock · 35,000 shares Expires 2036-05-27 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following May 28, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| April 20, 2026 Filed May 14, 2026 21:15 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 264,759 | $0.00 Strike: $6.44 | $0.00 |
DisclosureSEC source: 0001104659-26-061327 · tm2614553-2_4seq1.xml · derivative · entry 1 Grauer Andreas · CIK 0001770511 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,759 Underlying: Series A Common Stock · 264,759 shares Expires 2036-04-19 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on April 20, 2027, with the remaining 75% vesting over thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 22:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $29.41 | $0.00 |
DisclosureSEC source: 0000899243-21-005183 · doc4.xml · derivative · entry 1 Grauer Andreas · CIK 0001770511 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-02-04 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 5, 2021, so that the total number of shares subject to this option becomes fully vested and exercisable on February 5, 2025. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 22:09 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $13.56 | $0.00 |
DisclosureSEC source: 0000899243-20-004040 · doc4.xml · derivative · entry 1 Grauer Andreas · CIK 0001770511 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-02-06 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 7, 2020, so that the total number of shares subject to this option becomes fully vested and exercisable on February 7, 2024. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 17:36 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 425,000 | $0.00 Strike: $11.29 | $0.00 |
DisclosureSEC source: 0000899243-19-009521 · doc4.xml · derivative · entry 1 Grauer Andreas · CIK 0001770511 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,000 Underlying: Common Stock · 425,000 shares Expires 2029-03-31 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 25% of the total number of shares on the one-year anniversary of March 18, 2019 and 1/36th of the remaining number of shares on each monthly anniversary thereafter, so that the total number of shares subject to this option becomes fully vested and exercisable on March 18, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.